| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Departments of Molecular Biology (L.F., L.M.J., E.T., M.R., L.S., J.F., T.A.S.), Protein Engineering (R.C., B.M., R.V.), and Assay Technologies (J.-P.S., S.P.T.), Genentech, Inc., South San Francisco, California 94080
Address all correspondence and requests for reprints to: Timothy A. Stewart, Genentech Inc., 1 DNA Way, South San Francisco, California 94080. E-mail: timstewart{at}yahoo.com.
Hormonal control of metabolic rate can be important in regulating the imbalance between energy intake and expenditure that underlies the development of obesity. In mice fed a high-fat diet, human fibroblast growth factor 19 (FGF19) increased metabolic rate [1.53 ± 0.06 liters O2/h·kg0.75 (vehicle) vs. 1.93 ± 0.05 liters O2/h·kg0.75 (FGF19); P < 0.001] and decreased respiratory quotient [0.82 ± 0.01 (vehicle) vs. 0.80 ± 0.01 (FGF19); P < 0.05]. In contrast to the vehicle-treated mice that gained weight (0.14 ± 0.05 g/mouse·d), FGF19-treated mice lost weight (–0.13 ± 0.03 g/mouse·d; P < 0.001) without a significant change in food intake. Furthermore, in addition to a reduction in weight gain, treatment with FGF19 prevented or reversed the diabetes that develops in mice made obese by genetic ablation of brown adipose tissue or genetic absence of leptin. To explore the mechanisms underlying the FGF19-mediated increase in metabolic rate, we profiled the FGF19-induced gene expression changes in the liver and brown fat. In brown adipose tissue, chronic exposure to FGF19 led to a gene expression profile that is consistent with activation of this tissue. We also found that FGF19 acutely increased liver expression of the leptin receptor (1.8-fold; P < 0.05) and decreased the expression of acetyl coenzyme A carboxylase 2 (0.6-fold; P < 0.05). The gene expression changes were consistent with the experimentally determined increase in fat oxidation and decrease in liver triglycerides. Thus, FGF19 is able to increase metabolic rate concurrently with an increase in fatty acid oxidation.
This article has been cited by other articles:
 |
|
 |
|
  S. Talukdar, S. Bhatnagar, S. Dridi, and F. B. Hillgartner Chenodeoxycholic acid suppresses the activation of acetyl-coenzyme A carboxylase-{alpha} gene transcription by the liver X receptor agonist T0-901317 J. Lipid Res., December 1, 2007; 48(12): 2647 - 2663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wu, H. Ge, J. Gupte, J. Weiszmann, G. Shimamoto, J. Stevens, N. Hawkins, B. Lemon, W. Shen, J. Xu, et al. Co-receptor Requirements for Fibroblast Growth Factor-19 Signaling J. Biol. Chem., October 5, 2007; 282(40): 29069 - 29072. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Huang, C. Yang, Y. Luo, C. Jin, F. Wang, and W. L. McKeehan FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet Induced Fatty Liver Diabetes, October 1, 2007; 56(10): 2501 - 2510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Lin, M. Wang, C. Blackmore, and L. R. Desnoyers Liver-specific Activities of FGF19 Require Klotho beta J. Biol. Chem., September 14, 2007; 282(37): 27277 - 27284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Aslanidi, V. Kroutov, G. Philipsberg, K. Lamb, M. Campbell-Thompson, G. A. Walter, S. Kurenov, J. Ignacio Aguirre, P. Keller, K. Hankenson, et al. Ectopic expression of Wnt10b decreases adiposity and improves glucose homeostasis in obese rats Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E726 - E736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Sun, M. Malabunga, J. R. Tonra, R. DiRenzo, F. E. Carrick, H. Zheng, H.-R. Berthoud, O. P. McGuinness, J. Shen, P. Bohlen, et al. Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E964 - E976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kharitonenkov, V. J. Wroblewski, A. Koester, Y.-F. Chen, C. K. Clutinger, X. T. Tigno, B. C. Hansen, A. B. Shanafelt, and G. J. Etgen The Metabolic State of Diabetic Monkeys Is Regulated by Fibroblast Growth Factor-21 Endocrinology, February 1, 2007; 148(2): 774 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wente, A. M. Efanov, M. Brenner, A. Kharitonenkov, A. Koster, G. E. Sandusky, S. Sewing, I. Treinies, H. Zitzer, and J. Gromada Fibroblast Growth Factor-21 Improves Pancreatic {beta}-Cell Function and Survival by Activation of Extracellular Signal-Regulated Kinase 1/2 and Akt Signaling Pathways Diabetes, September 1, 2006; 55(9): 2470 - 2478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gutierrez, E. P. Ratliff, A. M. Andres, X. Huang, W. L. McKeehan, and R. A. Davis Bile Acids Decrease Hepatic Paraoxonase 1 Expression and Plasma High-Density Lipoprotein Levels Via FXR-Mediated Signaling of FGFR4 Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): 301 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Yu, F. Wang, C. Jin, X. Huang, and W. L. McKeehan Independent Repression of Bile Acid Synthesis and Activation of c-Jun N-terminal Kinase (JNK) by Activated Hepatocyte Fibroblast Growth Factor Receptor 4 (FGFR4) and Bile Acids J. Biol. Chem., May 6, 2005; 280(18): 17707 - 17714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Strack and R. W. Myers Modulation of Metabolic Syndrome by Fibroblast Growth Factor 19 (FGF19)? Endocrinology, June 1, 2004; 145(6): 2591 - 2593. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
